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Background/Aims: This study elucidated the prognostic factors for neurocardiogenic syncope in males in their late teens 
and early twenties.
Methods: Tilt-table testing (TTT) was performed on 665 males (age range, 17 to 27 years) following the Italian protocol. 
The subjects were tilted head-up at a 70° angle on a table for 30 minutes during the passive phase. If the passive phase 
was negative, the subjects were given sublingual nitroglycerin and tilted to the same angle for 20 minutes during the drug-
provocation phase. The subjects with positive results were followed without medication. We analyzed factors related to the 
recurrence rate of syncope.
Results: Of 305 subjects (45.8%) with positive results, 223 (age range, 18 to 26 years) were followed for 12 months. 
The frequency of previous syncopal episodes ≥ 4 (p = 0.001) and a positive result during the passive phase (p = 0.022) 
were significantly related to a high recurrence rate. A positive result during the early passive phase (≤ 12 minutes) was 
significantly related to a higher recurrence rate than was that during the late passive phase (> 12 minutes; p = 0.011).
Conclusions: A positive result during the early passive phase of TTT and frequent previous syncopal episodes were 
prognostic factors for neurocardiogenic syncope in men in their late teens and early twenties.
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INTRODUCTION
Neurocardiogenic syncope is the most common cause of 
syncope in patients without underlying disease [1]. Neu-
rocardiogenic syncope has a peak incidence in subjects 
in their late teens and early twenties [2]. Tilt-table testing 
(TTT) is used widely to diagnose neurocardiogenic syn-
cope. The positive rate of TTT with or without a history of 
syncope ranges from 23.8 to 74% [3-6]. Many research-
ers have studied treatments of neurocardiogenic syncope 
including salt intake [7], physical maneuvers [8,9], beta-
blockers [10,11], midodrine [12], fludrocortisones [13], par-
oxetine [14], and cardiac pacing [15]; however, the results 
are conflicting. In general, the prognosis of patients with 
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neurocardiogenic syncope is benign, although some pa-
tients experience not only recurrent syncopal episodes but 
also serious head injuries despite treatment. Therefore, 
the identification of high-risk patients is important for 
treatment and follow-up. The frequency of previous syn-
copal episodes has been reported to be the most powerful 
predictor of recurrent neurocardiogenic syncope [16-21]. 
No other prognostic factors have been confirmed for males 
in their late teens and early twenties. Therefore, this study 
sought to identify prognostic factors for neurocardiogenic 
syncope in males in their late teens and early twenties.
METHODS
Consecutive males with unexplained syncope seen 
between September 2006 and September 2008 were 
included. Subjects with underlying disease or abnormal 
electrocardiograms (ECGs) and those taking any medica-
tions were excluded. Abnormal ECGs included rhythms 
other than sinus rhythm, right- or left-axis deviation, left- 
or right-ventricular hypertrophy, Mobitz type 2 second-
degree atrioventricular block, complete atrioventricular 
block, left bundle-branch block, and pathological Q-wave 
and abnormal ST-segment or T-wave changes.
TTT was performed according to the Italian protocol 
[22,23]. The subjects fasted for at least 3 hours before the 
test. The subjects were monitored throughout testing with 
3-lead electrocardiography and automated blood pressure 
cuff measurements every 2 minutes. The TTT consisted 
of passive and drug-provocation phases. After a 5-minute 
rest in the supine position, the subjects were tilted head-
up to a 70° angle on the table for 30 minutes during the 
passive phase. If the passive phase was negative, the sub-
jects were given sublingual nitroglycerin (0.4 mg) and 
tilted to the same angle for another 20 minutes during the 
drug-provocation phase. The endpoint of the TTT was the 
induction of syncope with significant hypotension. Posi-
tive results were classified into the following three types 
[22,24]: type 1 (mixed) was defined as hypotension and 
heart rate 40-60/minutes; type 2 (cardioinhibitory) was 
defined as heart rate < 40/minutes or asystole for ≥ 3 sec-
onds; and type 3 (vasodepressor) was defined as pure hy-
potension without bradycardia. Hypotension was defined 
as decreased blood pressure causing syncope or signs of 
poor tissue perfusion. The subjects with positive results 
were educated on the prevention of syncope, including the 
avoidance of predisposing factors, lying down at the onset 
of prodromal symptoms, fluid or salt intake, and physical 
maneuvers. No medications were prescribed for subjects 
with positive results. The subjects were followed in the 
outpatient clinic or by telephone on a regular basis for 12 
months. All subjects provided informed consent.
Statistical analysis
We analyzed the frequency of previous syncope, the TTT 
phase that gave a positive result, the TTT duration until a 
positive result, the types of neurocardiogenic syncope, and 
the recurrence rate of syncope during the follow-up period. 
The results are expressed as the mean ± SD or median (in-
terquartile range, IQR) for data that were not distributed 
normally. The Mann-Whitney U test and Kruskal-Wallis 
test were used for statistical analysis of data that were not 
distributed normally. Univariate and multivariate logistic 
regression analyses were used to identify variables associ-
ated with the recurrence of syncope during the follow-up 
period. A p value < 0.05 was considered significant. The 
data were analyzed with the SPSS version 12.0 (SPSS Inc., 
Chicago, IL, USA).
RESULTS
Baseline characteristics
Of the 665 male subjects (mean age, 22.0 years; range, 
17 to 27) who underwent testing, 305 (45.8%) had positive 
results on TTT. Of the subjects with positive results, 82 
were excluded because of abnormal ECGs or loss to follow-
Tilt-table test (n = 665)  
Positive (n = 305)  Negative (n = 360)  
Exclusion (n = 82)
Drug provocation phase (n = 178 / 223) Passive phase (n = 45 / 223)
Figure 1. Flow diagram and number of subjects. Eighty-two 
patients were excluded because they were lost to follow-up or be-
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up (Fig. 1). We followed 223 subjects (mean age, 21.1 years; 
range, 18 to 26) for 12 months. The frequency of previous 
syncopal episodes was 3.4 ± 5.0 (Table 1).
Tilt-table test and follow-up results
There were 45 (20.2%) subjects with positive results 
during the passive phase and 178 (79.8%) during the drug-
provocation phase (Fig. 1). There were 146 (65.5%), 39 
(17.5%), and 38 (17.0%) type 1 to 3 subjects, respectively. 
Syncope recurred in 67 (30.0%) subjects. The frequency 
of recurrence of syncopal episodes during the follow-up 
period was 1.3 ± 2.4. No recurrences occurred in 95 of 116 
subjects (81.9%) with one previous syncopal episode, 36 of 
54 subjects (66.7%) with two or three syncopal episodes, 
and 25 of 53 subjects (47.2%) with four or more syncopal 
episodes.
Factors related to the recurrence of syncope 
The subjects with four or more previous syncopal epi-
sodes in their lifetime had significantly more recurrences 
of syncopal episodes than did those with fewer than four (1, 
2-3, and ≥ 4; 0 [IQR, 0 to 0.5], 0 [IQR, 0 to 2], and 3 [IQR, 
0 to 9.5], respectively; p = 0.001) (Fig. 2). The subjects with 
positive results during the passive phase had significantly 
more recurrences of syncope than did those with positive 
results only during the drug-provocation phase (1 [IQR, 0 
to 4] and 0 [IQR, 0 to 1], respectively; p = 0.022) (Fig. 3). 
The subjects (n = 7 of 45) with positive results during the 
early passive phase (≤ 12 minutes) had significantly more 
recurrences of syncopal episodes than did subjects (n = 38 
of 45) with positive results during the late passive phase 
(> 12 minutes) (4 [IQR, 3 to 7] and 0 [IQR, 0 to 4], respec-
tively; p = 0.011) (Fig. 3). However, there were no signifi-
cant differences between the subjects  with positive results 
during the early (≤ 10 minutes, n = 146 of 178) and late 
(> 10 minutes, n = 32 of 178) drug-provocation phases (0 
[IQR, 0 to 2] and 0 [IQR, 0 to 0.5], respectively; p = 0.614) 
or among the types of neurocardiogenic syncope (types 
1 to 3; 0 [IQR, 0 to 1], 0 [IQR, 0 to 3], and 0 [IQR, 0 to 3], 
respectively; p = 0.435) and the recurrence of syncope. 
Frequent previous syncopal episodes (≥ 4; p = 0.001) and 
positive results during the passive phase of TTT (p = 0.001) 
were significantly associated with the recurrence of syn-
cope (Table 2).
DISCUSSION
This prospective, observational study elucidated prog-
nostic factors for neurocardiogenic syncope in males in 
their late teens and early twenties in whom the incidence 
of neurocardiogenic syncope is high [2]. We found that 
most subjects (81.9%) with one previous syncopal episode 
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Figure 2. Recurrence of syncope according to the frequency of 
previous syncopal episodes. The results are expressed as the me-
dian (interquartile range). 
Table 1. Clinical characteristics of the subjects
Characteristics Values
Total no. of subjects 223
Age, yr 21.1 ± 1.6
male gender 223 (100)
Frequency of previous syncope, times 3.4 ± 5.0
No. of subjects with 1 episode    116 (52.0)
No. of subjects wwith 2-3 episodes    54 (24.2)
No. of subjects with ≥ 4 episodes    53 (23.8)
Interval between the last episode 
 and tilt-table testing, day
60.6 ± 92.2
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had no recurrence and that frequent previous syncopal 
episodes in their lifetime (≥ 4), a positive result during the 
passive phase of TTT, and positive results during the early 
passive phase (≤ 12 minutes) were significantly related to 
the recurrence rate of syncope. Therefore, a positive result 
during the early passive phase of TTT and frequent pre-
vious syncopal episodes might be prognostic factors for 
neurocardiogenic syncope in males in their late teens and 
early twenties. 
In previous studies, the frequency of syncope before 
TTT was the most powerful predictor for recurrent synco-
pe [16-20]. Female gender, a history of bronchial asthma, 
and the number of previous syncopal episodes may predict 
recurrences of neurocardiogenic syncope [21]. However, 
the TTT phase or period associated with positive results as 
prognostic factors have not been studied in males in their 
late teens and early twenties. 
Neurocardiogenic syncope occurs frequently during 
prolonged motionless standing, and the passive phase is 
similar to this situation. The drug-provocation phase is 
performed on subjects who can tolerate the passive phase. 
Such subjects were better able to tolerate prolonged mo-
tionless standing. Therefore, subjects with a positive result 
during the passive phase would tend toward a high recur-
rence rate of syncope. Furthermore, subjects with a posi-
tive result during the early passive phase could be more 
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Figure 3. Recurrence of syncope according to the phase with positive tilt-table testing results. (A) Comparison of subjects with positive 
results during the passive and drug-provocation phases. (B) Comparison of subjects with positive results during the early and late pas-
sive phases. The results are expressed as the median (interquartile range).
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Table 2. Univariate and multivariate logistic regression analyses to identify the variables that influence the recur-
rence of syncope
Variable
Univariate multivariate
p value p value OR 95% CI
Frequent previous syncopal episodes (≥ 4) 0.001 0.001 7.857 2.938 - 21.010
Positive result during the passive phase of TTT 0.002 0.001 5.504 2.390 - 12.676
Types of neurocardiogenic syncope 0.435 - - -
OR, odds ratio; CI, confidence interval; TTT, tilt-table testing.64    The Korean Journal of Internal medicine Vol. 27, No. 1, march 2012
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susceptible to a shorter duration of motionless standing.
The classification of neurocardiogenic syncope is based 
on the results of TTT [22,24]. The mechanisms of each 
type and the relationship between the type and prognosis 
are debatable [25].
For patients suspected of neurocardiogenic syncope, it 
is important to obtain a medical history and to perform 
TTT. Patients with positive results during the early passive 
phase of TTT and with more frequent episodes of previous 
syncope need to be followed closely and treated optimally.
Limitations
The follow-up period of our subjects was relatively short; 
therefore, future prospective studies are needed to ascer-
tain the recurrence of syncope in more subjects for longer 
periods of time at various centers. There are different TTT 
protocols (e.g., the Westminster protocol using isoproter-
enol for the drug-provocation phase). The Italian protocol 
with nitroglycerin is comparable to the Westminster pro-
tocol with isoproterenol [22,23].
Conclusions
A positive result during the early passive phase of TTT 
and frequent previous syncopal episodes are significant 
prognostic factors for neurocardiogenic syncope in males 
in their late teens and early twenties.
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